All In Biotech

Drug Trial Radar · NCT07335796

A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer

A Phase 2 Study of Androgen Deprivation Therapy and BMS986365 in High-Risk Localized Prostate Cancer Patients Prior to Radical Prostatectomy

Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

7

Actual

Start

Jan 9, 2026

Primary completion

Jan 9, 2030

Study completion Jan 9, 2030

Sponsor

Lead sponsor
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to find out whether BMS986365 in combination with degarelix, given before standard surgical treatment (radical prostatectomy), is a safe and effective treatment that causes few or mild side effects for people who have localized high-risk prostate cancer.

Conditions

  • Prostate Cancer

Interventions

  • BMS-986165Drug

    BMS986365 (CC-94676) is an androgen receptor (AR) ligand-directed degrader that was designed to target the AR for degradation in castration-resistant prostate cancer (CRPC)

  • DegarelixDrug

    Degarelix is a GnRH antagonist that blocks the action of GnRH on the pituitary and effectively suppresses testosterone production

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of pathologic complete response/pCRTime frame: 42 months

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

    Basking Ridge, New Jersey

  • Memorial Sloan Kettering Bergen (Limited Protocol Activities)

    Montvale, New Jersey

  • Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)

    Commack, New York

  • Memorial Sloan Kettering Westchester (Limited Protocol Activities)

    Harrison, New York

  • Memorial Sloan Kettering Cancer Center (All Protocol Activites)

    New York, New York

  • Memorial Sloan Kettering Nassau (Limited Protocol Activites)

    Rockville Centre, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.